Moneybags

AMRYT’S ‘MINI BLOCKBUSTER’ DRUGS SET TO REAP $1BN IN SALES

Date: September 9, 2021 - Moneybags

Joe Wylie

Joe Wylie


COMING ON top of the $153m acquisition of Aegerion as recently as September 2019, Amryt Pharma’s current $375m merger with Chiasma represents another major step for the company. As Amryt lost $106m last year, investors will be watching closely to see how CEO Joe Wiley performs and whether he really can deliver on the $1bn… Read more »

To access this content, you must be a Phoenix subscriber.

Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!

Subscribe Now! I'm a Subscriber

Related Articles: